AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQÂź) for Alopecia Areata
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQÂź) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with seve...